ClinicalTrials.gg
RecruitingNCT07159750EUREkAUpdated Sep 8, 2025

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

An observational study in Migraine, Episodic Migraine and Chronic Migraine, Headache, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 26 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Migraine Disorders with a site in Spain — 23 open to participants now, 35 under way, 15 of them phase 3. Migraine Disorders · Spain.

Planned enrollment
4th of 24
700 · median 231
Started
2024
with 9 others
Observational
24 of 97
10 open now
Primary completion
2026-01
later than 9 of 34 live
Registered
91st of 97
by date
Lead sponsor
4 of 97
Hospital Universitari Vall d'Hebron Research Institute

Among the 97 studies in Migraine Disorders with a site in Spain, this one is the 4th largest by planned enrollment of the 24 observational ones that give a count, is one of 10 that started in 2024, is one of 24 observational ones, reaches primary completion later than 9 of the 34 other live ones, and was the 91st registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

23 of the 97 studies in Migraine Disorders with a site in Spain are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Migraine Disorders with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

Read the detailed description

It is a 2-year, multicenter observational study. Patients who meet reimbursement criteria according to local regulations and willing to participate in the study will be included. Monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) will be started and baseline assessment will be conducted. There will be visits every 6 months to assess effectiveness, side-effects, PROMs, and elegibility to continue with the study drug. The observation of patients will last 2 years.

03

Conditions studied

  • Migraine
  • Episodic Migraine
  • Chronic Migraine, Headache

Keywords

  • Migraine
  • Prevention
  • Chronic Migraine
  • Episodic Migraine
  • galcanezumab
  • erenumab
  • fremanezumab
  • eptinezumab
  • rimegepant
  • atogepant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Episodic and chronic migraine patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Migraine diagnosis according to ICHD-III.
  • Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
  • Signature of .

Exclusion criteria

Exclusion Criteria:

  • Presence of headache different from migraine.
  • Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Migraine Patients

    Migraine patients who initiate a CGRP-targeted treatment

    Drug: CGRP antibody or gepant

Interventions

  • DrugCGRP antibody or gepant

    Patients will start anti-CGRP or its receptor antibody or gepants

06

What researchers measure

Primary outcomes

  1. Change in Monthly Headache Days and Monthly Migraine Days

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. HIT-6

    Change in HIT-6 (Headache Impact Test) scale, to assess migraine impact.

    Time frame: Through study completion, an average of 2 years

  2. MIDAS

    Change in MIDAS (Migraine Disability Assessment Scale) scale, to assess disability attributed to migraine.

    Time frame: Through study completion, an average of 2 years

  3. PGIC

    PGIC (Patien Global Impression of Change) scale will be used to assess impression of change in migraine patients.

    Time frame: Through study completion, an average of 2 years.

  4. BAI

    Change in BAI (Beck Anxiety Inventory) scale, to assess anxiety in migraine patients.

    Time frame: Through study completion, an average of 2 years.

  5. BDI-II

    Change in BDI-II (Beck's Depression Inventory, 2nd version) scale, to assess depression in migraine patients.

    Time frame: Through study completion, an average of 2 years.

  6. MSQ Version 2.1

    Changes in MSQ (Migraine-Specific Quality-of-Life) Version 2.1 scale, to assess patient's quality of life.

    Time frame: Through study completion, an average of 2 years.

  7. WPAI

    Changes in WPAI (Work Productivity and Activity Impairment) questionnaire, to assess how migraine impacts in work and productivity in migraine patients.

    Time frame: Through study completion, an average of 2 years.

  8. ISI

    Changes in ISI (Insomnia Severity Index) scale to assess insomnia in migraine patients.

    Time frame: Through study completion, an average of 2 years.

  9. ASC-12

    Changes in ASC-12 (Allodynia Symptom Checklist) scale, to assess allodynia in migraine patients.

    Time frame: Through study completion, an average of 2 years.

  10. m-TOQ

    m-TOQ (Migraine Treatment Optimization Questionnaire) scale will be used to assess the effectiveness of migraine treatment.

    Time frame: Through study completion, an average of 2 years.

07

Study locations

25 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2026, 24 months after the start.

Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 24 months is below that.

Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2025
First posted
Sep 8, 2025
StartActual
Jan 2, 2024
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07159750
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Jan 2, 2024
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Patricia Pozo-Rosich, MD, PhD
Contact
cefalea@vhir.org
(+34) 93 489 30 00 ext. 2479
Edoardo Caronna, MD, PhD
Contact
cefalea@vhir.org
(+34) 93 489 30 00 ext. 2479
Patricia Pozo-Rosich, MD, PhD
principal investigator · Vall d'Hebron University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion